Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model
Author:
Publisher
Elsevier BV
Subject
Cell Biology,Dermatology,Molecular Biology,Biochemistry
Reference57 articles.
1. Phenotype plasticity as enabler of melanoma progression and therapy resistance;Arozarena;Nat Rev Cancer,2019
2. GLO1 overexpression in human malignant melanoma;Bair;Melanoma Res,2010
3. Progression of RAS-mutant leukemia during RAF inhibitor treatment;Callahan;N Engl J Med,2012
4. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor;Caporali;Int J Oncol,2016
5. BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma;Chiappetta;Appl Immunohistochem Mol Morphol,2015
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance;Heliyon;2023-07
2. Systemic deuteration of SCID mice using the water‐isotopologue deuterium oxide (D2O) inhibits tumor growth in an orthotopic bioluminescent model of human pancreatic ductal adenocarcinoma;Molecular Carcinogenesis;2023-02-02
3. Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling;Cancers;2022-12-10
4. Mefloquine induces ER stress and apoptosis in BRAFi‐resistant A375‐BRAF V600E /NRAS Q61K malignant melanoma cells targeting intracranial tumors in a bioluminescent murine model;Molecular Carcinogenesis;2022-04-13
5. Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming;Frontiers in Oncology;2022-03-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3